Develops epinephrine prodrugs for severe allergic reactions.
Jun 2026Revenue $54.1M/yrExpenses $107M/yr
No trendCash runway ≈ 2.1 years from Jun 2026
Figures by year
When will Aquestive Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $54.1M and expenses $107M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $44.5M | $116M | −$71.1M |
| Dec 2024 | $57.6M | $88.3M | −$30.8M |
| Dec 2023 | $50.6M | $65.7M | −$15.1M |
| Dec 2022 | $47.7M | $89.7M | −$42.1M |
| Dec 2021 | $50.8M | $85.5M | −$34.7M |
| Dec 2020 | $45.8M | $88.7M | −$42.9M |
| Dec 2019 | $52.6M | $105M | −$52.7M |
| Dec 2018 | $67.4M | $116M | −$48.9M |
| Dec 2017 | $66.9M | $67.0M | −$113K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.